Fosun Pharmaceutical (600196.SH): The holding subsidiary signs the “Amendment to the License Agreement” and the “Agreement on Termination of the Cooperation and License Agreement”
Gelonghui, May 21丨Fosun Pharmaceutical (600196.SH) announced that on May 21, 2024, Fuhong Hanlin and Palleon signed (1) the “Amendment to the Cooperation and License Agreement” (“Amendment to the Cooperation and License Agreement”, “Amendment to the License Agreement”), and (2) “Based on comprehensive considerations of market competition and the latest research progress mutualAgreementToTerminateLicensedPr
Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Shareholders Have Endured a 61% Loss From Investing in the Stock Three Years Ago
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But long term Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) sharehol
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Fosun Pharma Unit Fosun Health to Receive Capital Injection From Foshan Chanxi City Investment
Fosun Health, a unit of Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196), will receive a capital injection from Foshan Chanxi City Investment, according to a Wednesday filing on the Shangh
Fuhong Hanlin, an affiliate of Fosun Pharmaceutical (600196.SH), was approved for drug clinical trials
Fosun Pharmaceutical (600196.SH) announced that Shanghai Fuhong Hanlin Biotechnology Co., Ltd., a holding subsidiary of the company...
Fosun Pharmaceutical (600196.SH): Holding subsidiary Fosun Health signs capital increase and share expansion agreement
Gelonghui, May 14, 丨 Fosun Pharmaceutical (600196.SH) announced that according to the “Cooperation Agreement” reached between Fosun Health, its holding subsidiary, and the Chancheng District People's Government of Foshan City on February 23, 2024, the Company's holding subsidiary Fosun Health signed a “Capital Increase Agreement” with Foshan Chanxi City Investment on May 14, 2024. According to the “Capital Increase Agreement”, Foshan Chanxi City Investment plans to designate entities (including funds, holding companies or other entities) to invest RMB 30,000 million in a pre-investment valuation of RMB 10.2 billion and pledge Fosun Health's additional registered capital of RMB 156.17 million (i.e.
Fosun Pharma Unit Gets China Marketing Approval for Schizophrenia Tablets
China's medical products administrator granted Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) unit Shanghai Chongqing Yaoyou Pharmaceutical marketing registration approval for its aripip
Fosun Pharmaceutical (02196.HK) plans to hold 2023 and 2024 first quarter results briefings on May 17
Gelonghui, May 9, 丨 Fosun Pharmaceutical (02196.HK) announced that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”) will disclose its 2023 annual report on March 27, 2024, and the first quarter report of 2024 on April 30, 2024. In order to facilitate investors to have a more comprehensive and in-depth understanding of the Group's (that is, the company and holding subsidiaries/units, the same below) results and operations for 2023 and the first quarter of 2024, the company is scheduled to be held on May 17, 2024 from 15:00-16:30 p.m.
Fosun Pharmaceuticals (02196) guarantees its holding subsidiary
Fosun Pharmaceutical (02196) announced that the company intends to apply for the principal amount of the holding subsidiary Fosun Antekin from the Bank of Chengdu...
US FDA Grants Clinical Trial Approval for Fosun Unit's Gastric Cancer Tablets
The US Food and Drug Administration granted clinical trial approval to Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) for unit Shanghai Henlius Biotechnology's HLX22 tablets indicated fo
Fosun Pharmaceutical (02196.HK) has yet to repurchase shares
Gelonghui, May 6, 丨 Fosun Pharmaceutical (02196.HK) issued an announcement. From March 26, 2024 (that is, the date the board of directors reviewed and approved the repurchase plan) to April 30, 2024, the company has not yet repurchased shares under the repurchase plan.
Fosun Pharma's Q1 Profit Slumps 38%
Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) posted a net profit attributable to owners of 609.7 million yuan in the first quarter of 2024, slumping 38.2% from 987 million yuan a year
Shanghai Fosun Pharmaceutical 1Q Net CNY609.73M Vs. Net CNY986.97M >0656.HK
Shanghai Fosun Pharmaceutical 1Q Net CNY609.73M Vs. Net CNY986.97M >0656.HK
復星醫藥:2024年第一季度報告
Fosun Pharmaceutical (02196): Fosun Pharmaceutical Industries and Kite Pharma plan to renew and provide additional loans totaling no more than 67 million US dollars to Fosun Kate based on their respective shareholding ratios
Fosun Pharmaceutical (02196) issued an announcement to satisfy Fosun Kate Biotechnology Co., Ltd. (hereinafter referred to as “Fosun Kate...
Fosun Pharmaceutical (02196, 600196.SH) 2024 Quarterly Report: Innovative achievements are being realized at an accelerated pace, and various new products are comprehensively advancing the commercialization process
During the reporting period, Fosun Pharmaceutical achieved revenue of 10.157 billion yuan, excluding COVID-related products, and achieved positive year-on-year growth in revenue. Net cash flow from operating activities was $917 million, up 5.05% year over year.
Zhitong Hong Kong Stock Investment Calendar | April 29
According to statistics from the Zhitong Finance App, on April 29, 2024, the investment log of Hong Kong stock listed companies is as follows: Category Company Performance Announcement Date: Bank of Zhengzhou Xinte Energy China Galaxy China Communications Construction Hyperion Fosun Pharmaceuticals CRRC Red Star Macalline Shanghai Electric Dongfang Electric Shareholders' Meeting Held Japan-China Guangzhou Nuclear Power Jilin Changlong Pharmaceutical Seaport Enterprise Delin International Asia Backup CLP Holdings Pacific Network China Building Materials Dividend Shenwei Pharmaceutical (excluding Clean Day) Comfort Project (dividend day) Chunquan Industrial Trust (dividend date) 361 degrees (excluding cleaning day) Prada (excluding clean day) ) Times Group Holdings (dividends)
Fosun Pharmaceutical (600196.SH): Cycloserine capsules approved for drug registration
Gelonghui, April 24 | Fosun Pharmaceutical (600196.SH) announced that the marketing registration application for cycloserine capsules (referred to as “the new drug”) independently developed by Shenyang Hongqi Pharmaceutical Co., Ltd., a holding subsidiary of the company, for the treatment of active tuberculosis and extrapulmonary tuberculosis (including renal tuberculosis) caused by tuberculosis bacteria sensitive to this drug and treated with first-line anti-tuberculosis drugs (such as streptomycin, isoniazid, rifampicin, and ethambutol) with poor treatment effects by first-line anti-tuberculosis drugs (such as streptomycin, isoniazid, rifampicin, and ethambutol), was recently approved by the State Drug Administration.
復星醫藥:二零二三年年報
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) Doing What It Can To Lift Shares
With a price-to-earnings (or "P/E") ratio of 25.5x Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) may be sending bullish signals at the moment, given that almost half of all companies i
No Data